Skip to main content

Advertisement

SpringerLink
Log in

Stroke prevention in diabetic and other high cardiovascular risk patients

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetes is a major risk factor for stroke that is usually associated with risk factors such as hypertension, obesity, albuminuria, and dyslipidemia. Furthermore, atrial fibrillation and heart failure, two of the most important risk factors of stroke, are common in the diabetic population. With the rising epidemic of diabetes, the incidence of stroke is also on the rise. Implementations of effective stroke prevention strategies appear to be the most rational option to curb this growing epidemic. In this review, we examine the epidemiologic and the pathophysiologic association between stroke and diabetes, highlighting the population-based stroke preventive measures. These include hygienic and lifestyle changes, that if applied effectively could offer a great potential for stroke prevention and reduction of the cardiovascular burden in the diabetic populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association: Heart and stroke statistics update, 1999. Available at http://www.americanheart.org/statistics/ index.html. Accessed on July 29, 2002.

  2. Straus SE, Majumdar SR, McAlister FA: New evidence for stroke prevention. JAMA 2002, 288:1388–1395.

    Article  PubMed  Google Scholar 

  3. Sacco RL, Benjamin EJ, Broderick AJ, et al.: American Heart Association Prevention Conference IV prevention and rehabilitation of stroke: risk factors. Stroke 1997, 28:1507–1517.

    PubMed  CAS  Google Scholar 

  4. Goldstein LB, Adams R, Becker K, et al.: Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Circulation 2001, 103:163–182.

    PubMed  CAS  Google Scholar 

  5. D'Agnostino RB, Wolf PA, Belanger AJ, et al.: Stroke risk profile: adjustment for antihypertensive medication: the Framingham Study. Stroke 1994, 25:40–43.

    Google Scholar 

  6. Pearson TA, Bazzarre TL, Daniels SR, et al.: American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003, 107:645–651.

    Article  PubMed  Google Scholar 

  7. Teng J, Mayo NE, Latimer E, et al.: Costs and caregiver consequences of early supported discharge for stroke patients. Stroke 2003, 34:528–536.

    Article  PubMed  Google Scholar 

  8. Gillum RB, Sempos CT: The end of the long-term decline in stroke mortality in the United States? Stroke 1997, 28:1527–1529.

    PubMed  CAS  Google Scholar 

  9. McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718–723.

    Article  PubMed  Google Scholar 

  10. Fagan TC, Sowers JR: Type 2 diabetes mellitus. Greater cardiovascular risks and greater benefits of therapy. Arch Intern Med 1999, 159:1033–1034.

    Article  PubMed  CAS  Google Scholar 

  11. Sacco RL: Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes Metab 2002, 4(suppl 1):S27-S34.

    Article  PubMed  Google Scholar 

  12. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233–240.

    Article  PubMed  CAS  Google Scholar 

  13. Palsinelli WA, Levy PE, Sigsbee B, et al.: Increased damaged after ischemic attacks in patients with hyperglycemia with without the established diagnosis of diabetes mellitus. Am J Med 1983, 74:540–544.

    Article  Google Scholar 

  14. Olesen J, Leonardi M: The burden of brain diseases in Europe. Eur J Neurol 2003, 10:471–477.

    Article  PubMed  CAS  Google Scholar 

  15. Levi CR, Magin PJ, Nair BR: Primary stroke prevention: refining the "high risk" approach. Med J Aust 2002, 176:303–304.

    PubMed  Google Scholar 

  16. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025. Prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414–1431.

    Article  PubMed  CAS  Google Scholar 

  17. Davis TM, Millens H, Stratten JM, et al.: Risk factors for stroke type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999, 159:1097–1103.

    Article  PubMed  CAS  Google Scholar 

  18. Green A, Christian Hirsch N, Pramming SK: The changing world demography of type 2 diabetes. Diabetes Metab Res Rev 2003, 19:3–7.

    Article  PubMed  Google Scholar 

  19. Pedersen O, Gaede P: Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism 2003, 52(8 suppl 1):19–23.

    Article  PubMed  CAS  Google Scholar 

  20. Lighthood JM, Glantz SA: Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997, 96:1089–1096.

    Google Scholar 

  21. Sacco Rl, Gan R, Boden-Albala B, et al.: Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. Stroke 1998, 29:380–387.

    PubMed  CAS  Google Scholar 

  22. Orozco-Valero M: Large therapeutic studies in elderly patients with hypertension. J Hum Hypertens 2002, 16(suppl 1):S38-S43.

    Article  PubMed  Google Scholar 

  23. Sacco RL, Boden-Albala B, Abel G, et al.: Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study. Stroke 2001, 32:1725–1731.

    PubMed  CAS  Google Scholar 

  24. Kothari V, Stevens RJ, Adler AI, et al.: UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002, 33:1776–1781.

    Article  PubMed  Google Scholar 

  25. Lank S, Ma JT, Woo E, et al.: High prevalence of undiagnosed diabetes among Chinese patients with ischemic stroke. Diabetes Res Clin Pract 1991, 14:133–137.

    Article  Google Scholar 

  26. Kagan A, Popper JS, Rhoads GG: Factors related to stroke incidence in Hawaii in Japanese men. Stroke 1980, 12:14–21.

    Google Scholar 

  27. Burchfiel CM, Curb JD, Rodriguez BL, et al.: Glucose intolerance and 22-year stroke incidence: the Honolulu Heart. Stroke 1994, 25:951–957.

    PubMed  CAS  Google Scholar 

  28. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979, 241:2035–2038.

    Article  PubMed  CAS  Google Scholar 

  29. Webster P: The natural history of stroke in diabetic patients. Acta Med Scand 1980, 207:417–424.

    Google Scholar 

  30. Gray CS, Taylor R, French FM, et al.: The prognostic value of stress hyperglycemia and previously unrecognized diabetes in acute stroke. Diabet Med 1987, 4:237–240.

    Article  PubMed  CAS  Google Scholar 

  31. Wass CT, Lanier WL: Glucose modulation of ischemic brain injury: review and clinical recommendations. Mayo Clin Proc 1996, 71:801–812.

    PubMed  CAS  Google Scholar 

  32. Smith ML, von Hanwehr R, Siesjo BK: Changes in extra- and intracellular pH in the brain during and following ischemia in hyperglycemic and in moderately hypoglycemic rats. J Cereb Blood Flow Metab 1986, 6:574–583.

    PubMed  CAS  Google Scholar 

  33. Marsh WR, Anderson RE, Sundt TM Jr: Effect of hyperglycemia on brain pH levels in areas of focal incomplete cerebral ischemia in monkeys. J Neurosurg 1986, 65:693–696.

    PubMed  CAS  Google Scholar 

  34. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). U.K. Prospective Diabetes Study Group [no authors listed]. Lancet 1998, 352:854-865.

  35. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts: prospective studies collaboration [no authors listed]. Lancet 1995, 257:949-952.

  36. Macmahon S: The effects of antihypertensive drug treatment on the incidence of stroke and of coronary heart disease. Clin Exp Hypertens 1989, 11:807–823.

    CAS  Google Scholar 

  37. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [no authors listed]. JAMA 1991, 265:3255-3264.

  38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703-713.

  39. Curb JD, Pressel SL, Cutler J, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886–1892.

    Article  PubMed  CAS  Google Scholar 

  40. Birkenhager WH, Staessen JA, Gasowski J, de Leeuw PW: Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 2000, 13:232–237.

    PubMed  CAS  Google Scholar 

  41. Bakris GL, Gaxiola E, Messerli FH, et al.: Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril study. Hypertension 2004, 44:637–642. This landmark study compared antihypertensive treatment strategies with verapamil-SR to a β-blocker-based treatment in patients with CHD and diabetes. It demonstrated that verapamil SR-based strategy is as effective as β-blocker-based treatment in this high cardiovascular risk population, thus offering an alternative therapy for those who cannot tolerate β blockade.

    Article  PubMed  CAS  Google Scholar 

  42. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results from HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators [no authors listed]. Lancet 2000, 355:253-259.

  43. Sowers JR, Epstein M, Frolich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.

    PubMed  CAS  Google Scholar 

  44. Randomized trial of a perendopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack: Progress Collaborative Group [no authors listed]. Lancet 2001, 358:1033-1041.

  45. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  46. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031. Designed to test the hypothesis that at the same BP values, valsartan, an ARB, would be more effective in reducing CVD morbidity and mortality, compared with amlodipine-based treatment. In this study, which included 15,245 patients with a mean follow-up of 4.2 years, the main outcome of cardiac disease as well as stroke did not differ between the two treatment arms. However, there was a significantly lower BP reduction with the amlodipine-treated group.

    Article  PubMed  CAS  Google Scholar 

  47. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  48. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26(suppl 1):S80-S82.

    PubMed  Google Scholar 

  49. Adjusted-dose warfarin versus low intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial [no authors listed]. Lancet 1996, 348:633-638.

  50. Consensus conference on atrial fibrillation in hospital and general practice. Final consensus statement. Proc R Coll Physicians Edinb 1999, 29(suppl 6):2-3.

  51. Stigmayr B, Asplund K: Diabetes as a risk factor for stroke: a population perspective. Diabetologia 1995, 38:1061–1068.

    Google Scholar 

  52. Lithner F, Asplund K, Eriksson S, et al.: Clinical characteristics in diabetic stroke patients. Diabetes Metab 1988, 14:15–19.

    CAS  Google Scholar 

  53. Lairikyengbam SK, Anderson MH, Davies AG: Present treatment options for atrial fibrillation. Postgrad Med J 2003, 79:67–73.

    Article  PubMed  CAS  Google Scholar 

  54. Levy S, Breithardt G, Campbell RWF, et al.: Atrial fibrillation: current knowledge and recommendation for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998, 19:1294–1320.

    Article  PubMed  CAS  Google Scholar 

  55. Petersen P, Boysen G, Godtfredsen J, et al.: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989, 1:175–178.

    Article  PubMed  CAS  Google Scholar 

  56. Stroke Prevention in Atrial Fibrillation Study: final results [no authors listed]. Circulation 1991, 84:527-539.

  57. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators [no authors listed]. N Engl J Med 1990, 323:505-1511.

  58. Ezekowitz MD, Bridgers SL, James KE, et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327:1406–1412.

    Article  PubMed  CAS  Google Scholar 

  59. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. European Atrial Fibrillation Trial Study Group [no authors listed]. Lancet 1993, 342:1255-1262.

  60. Albers GW, Dalen JE, Laupacis A, et al.: Antithrombotic therapy in atrial fibrillation. Chest 2001, 119:194S-206S.

    Article  PubMed  CAS  Google Scholar 

  61. Hart RG, Halperin JL, McBride R, et al.: Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol 2000, 57:326–332.

    Article  PubMed  CAS  Google Scholar 

  62. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. The DAMAD Study Group [no authors listed]. Diabetes 1989, 38:491-498.

  63. Cote R, Battista RN, Abrahamowicz M, et al.: Lack of effect of ASA in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Intern Med 1995, 123:649–655.

    PubMed  CAS  Google Scholar 

  64. deGaetanoG: Collaborative Group of the Primary Prevention Project: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001, 357:89–95.

    Article  PubMed  Google Scholar 

  65. Rolka DB, Fagot-Campagna A, Narayan KM: Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001, 24:197–201.

    Article  PubMed  CAS  Google Scholar 

  66. American Diabetes Association: Aspirin therapy in diabetes. Diabetes Care 2000, 23(suppl 1): S61-S62.

    Google Scholar 

  67. Iso H, Jacobs DR Jr, Wentworth D, et al.: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989, 320:904–910.

    Article  PubMed  CAS  Google Scholar 

  68. Qizilbash N, Jones L, Warlow C, et al.: Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ 1991, 303:605–609.

    Article  PubMed  CAS  Google Scholar 

  69. Sacco RL, Benson RT, Kargman DE, et al.: High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001, 285:2729–2735.

    Article  PubMed  CAS  Google Scholar 

  70. Callahan A: Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol 2001, 88:33J-37J.

    Article  PubMed  CAS  Google Scholar 

  71. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.

    Article  PubMed  Google Scholar 

  72. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  73. The Internet Stroke Site: Stroke prevention by aggressive reduction in cholesterol levels (SPARCL). Available at http:// www.neuro.wustl.edu/stroke/trials. Accessed on July 29, 2002.

  74. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1451–1458.

    Article  PubMed  CAS  Google Scholar 

  75. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486-2497.

  76. Fine-Edelstein JS, Wolf PA, O'Leary DH, et al.: Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994, 44:1046–1050.

    PubMed  CAS  Google Scholar 

  77. Chambers BR, Norris JW: Outcome in patients with asymptomatic neck bruits. N Engl J Med 1986, 315:860–865.

    Article  PubMed  CAS  Google Scholar 

  78. Bogousslavsky J, Despland PA, Regli F: Asymptomatic tight stenosis of the internal carotid artery: long-term prognosis. Neurology 1986, 36:861–863.

    PubMed  CAS  Google Scholar 

  79. Barnett HJ, Gunton RW, Eliasziw M, et al.: Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA 2000, 283:1429–1436.

    Article  PubMed  CAS  Google Scholar 

  80. Inzitari D, Eliasziw M, Gates P, et al.: The causes and risk of stroke in patients with asymptomatic internal carotid artery stenosis. N Engl J Med 2000, 342:1693–1700.

    Article  PubMed  CAS  Google Scholar 

  81. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group [no authors listed]. Stroke 1991, 22:1229-1235.

  82. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group [no authors listed]. Mayo Clin Proc 1992, 67:513-518.

  83. Hobson RWI, Weiss DG, Fields WS, et al.: Efficacy of carotid endarterectomy for asymptomatic carotid stenosis: the Veterans Affairs Cooperative Study Group. N Engl J Med 1993, 328:221–227.

    Article  PubMed  Google Scholar 

  84. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study [no authors listed]. JAMA 1995, 273:1421-1428.

  85. Blankenhorn DH, Hodis HN: George Lyman Duff Memorial Lecture: arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994, 14:177–192.

    PubMed  CAS  Google Scholar 

  86. Bots ML, Hoes AW, Koudstaal PJ, et al.: Common carotid intimamedia thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997, 96:1432–1437.

    PubMed  CAS  Google Scholar 

  87. Lonn EM, Yusuf S, Dzavik V, et al.: Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103:919–925.

    PubMed  CAS  Google Scholar 

  88. Macmahon S, Sharpe N, Gamble G, et al.: Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy. Circulation 1998, 97:1784–1790.

    PubMed  CAS  Google Scholar 

  89. Mukherjee D, Yadav JS: Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. Am Heart J 2002, 144:753–759.

    Article  PubMed  Google Scholar 

  90. Wolf PA, Clagett GP, Easton JD, et al.: Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professional from the Stroke Council of the American Heart Association. Stroke 1999, 30:1191–1194.

    Google Scholar 

  91. Albers GW, Hart RG, Lutsep HL, et al.: AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the ad hoc committee on guidelines for the management of transient ischemic attacks, Stroke Council, American Heart Association. Stroke 1999, 30:2502–2511.

    PubMed  CAS  Google Scholar 

  92. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial [no authors listed]. Lancet 2001, 357:1729-1737.

  93. Naylor AR, Bolia A, Abbott RJ, et al.: Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J Vasc Surg 1998, 28:326–334.

    Article  PubMed  CAS  Google Scholar 

  94. Gray WA: A cardiologist in the carotids. J Am Coll Cardiol 2004, 43:1602–1605.

    Article  PubMed  Google Scholar 

  95. HobsonRW2nd, Howard VJ, Roubin GS, et al.: Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg 2004, 40:1106–1111.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Stroke and Critical Care, Department of Neurology, Columbia University Medical Center, 710 West 168th Street, Room 552, 10032, New York, NY, USA

    Tanja Rundek MD, PhD

Authors
  1. Fadi El-Atat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanja Rundek MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James R. Sowers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samy I. McFarlane MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Atat, F., Rundek, T., Sowers, J.R. et al. Stroke prevention in diabetic and other high cardiovascular risk patients. Curr Diab Rep 5, 200–207 (2005). https://doi.org/10.1007/s11892-005-0010-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-005-0010-7

Keywords

Search

Navigation